Government Pharmaceutical Organization (GPO)
Government Pharmaceutical Organization (GPO) is the Thai state-owned pharmaceutical manufacturer under the Ministry of Public Health. Produces essential medicines, generic pharmaceuticals, vaccines, and active pharmaceutical ingredients (APIs) to ensure national drug security and affordable access. Supplies government hospitals via GPO catalogue procurement. Operates manufacturing facilities meeting GMP standards and is mandated to produce strategic medicines including antiretrovirals, cancer drugs, and pandemic-response compounds. GPO's compulsory-licensing exercises on patented drugs have been landmark global health-policy events.
Snapshot
Headline numbers a buyer checks first.
Established
1966
Ongoing
State enterprise under Ministry of Public Health
Annual revenue
~THB 8–9 bn
FY2023
Essential medicines produced
~400+ items
2023
Reports to
Ministry of Public Health
Ongoing
Profile overview
Government Pharmaceutical Organization (GPO) is the Thai state-owned pharmaceutical manufacturer under the Ministry of Public Health. Produces essential medicines, generic pharmaceuticals, vaccines, and active pharmaceutical ingredients (APIs) to ensure national drug security and affordable access. Supplies government hospitals via GPO catalogue procurement. Operates manufacturing facilities meeting GMP standards and is mandated to produce strategic medicines including antiretrovirals, cancer drugs, and pandemic-response compounds. GPO's compulsory-licensing exercises on patented drugs have been landmark global health-policy events.
Product and service lines
Essential medicines
Generic drug production
Manufactures ~400 essential medicine formulations for government hospital procurement. GPO catalogue covers antibiotics, antiretrovirals, cardiovascular, and diabetes drugs at controlled prices 30-70% below branded equivalents.
Vaccines
Vaccine and biological production
Produces select vaccines for the national immunisation programme including influenza and Japanese encephalitis vaccines. COVID-19 vaccine fill-and-finish operations expanded GPO's biologicals capacity during the pandemic.
Strategic reserves
Pandemic preparedness
Mandated to maintain national drug-security stockpiles for critical medicines. Compulsory licensing exercises on branded ARV and cancer drugs (2006-2007) were landmark global health-policy precedents cited in WTO Doha debates.
API
Active pharmaceutical ingredients
Produces select APIs domestically to reduce import dependency. Paracetamol, amoxicillin, and ARV APIs are priority domestic-production targets under Thailand's Pharmaceutical Industry Development Master Plan.
Thai pharmaceutical market structure
Key sector players by segment, 2024
GPO
Type
State enterprise
Primary segment
Generics, vaccines, APIs
Channel
Government hospital procurement
Mega Lifesciences (MEGA)
Type
Listed private
Primary segment
Branded generics, emerging markets
Channel
Pharmacy, modern trade, ASEAN export
Type
Private
Primary segment
Generics, OTC domestic
Channel
Hospital, pharmacy
Type
Private
Primary segment
Generics manufacturing
Channel
Hospital, export
Multinational (Pfizer, Novartis, etc.)
Type
MNC
Primary segment
Branded specialty
Channel
Private hospital, specialist
| Entity | Type | Primary segment | Channel |
|---|---|---|---|
| GPO | State enterprise | Generics, vaccines, APIs | Government hospital procurement |
| Mega Lifesciences (MEGA) | Listed private | Branded generics, emerging markets | Pharmacy, modern trade, ASEAN export |
| Thai Nakorn Patana | Private | Generics, OTC domestic | Hospital, pharmacy |
| Siam Pharmaceutical | Private | Generics manufacturing | Hospital, export |
| Multinational (Pfizer, Novartis, etc.) | MNC | Branded specialty | Private hospital, specialist |
Key drivers 2025-2026
Policy
Compulsory licensing authority
GPO retains authority to trigger compulsory licensing of patented drugs under TRIPS flexibilities. Rising cancer-drug costs and hepatitis-C treatment demand create ongoing political pressure to use this authority on high-priced specialty medicines.
Industrial
API localisation push
MoPH Pharma Master Plan targets 50% domestic API production by 2027. GPO's API expansion at its Nong Khae plant is the anchor project. Success reduces Thailand's USD 2B annual pharmaceutical API import bill.
Procurement
UCS drug budget pressure
30-Baht Universal Coverage Scheme drug budget is perennially underfunded. GPO's low-cost catalogue procurement is the primary cost-management lever for NHSO, giving GPO structural demand stability regardless of private-sector competition.
Where this profile is featured
Reports that reference this entity in their operator concentration or analysis.
Featured in
The Thai Pharma Import Lane: Multinational Brands, Thai-FDA Pathway...
Thai state-owned pharmaceutical anchor; structural domestic-generic leader.
Featured in
Thai Cannabis: From 2022 Decriminalisation to 2025 Recriminalisatio...
State-owned pharma; medical-cannabis programme.
Featured in
Thai Pharmaceutical: GPO State Pharma, Generic Production, and the ...
State-owned pharma; medical-cannabis programme.
Related Market profiles
Peers, parents, partners, agencies, and other Pharmaceuticals actors.
Partner
Ministry of Public Health Thailand (MoPH)
Operates under MoPH mandate as national essential-medicines manufacturer.
Open Market profile →
Sector peer
Government Pharmaceutical Organisation (GPO)
Thai state pharmaceutical manufacturer; generics, HIV ARV, biosimilar, Strategic Stockpile; FY2024 revenue ~ $463.8M.
Open Market profile →
Sector peer
GSK Thailand
UK-parent MNC originator Thai subsidiary; respiratory, vaccines, HIV, oncology; ~8% Thai market value share.
Open Market profile →
Sector peer
Mega Lifesciences
Largest Thai-listed pharma by revenue; emerging-market distribution franchise; FY2024 revenue ~ $463.8M.
Open Market profile →
Reports featuring this profile
Thailand AI Drug Discovery & Pharma-Biotech 2027 Market Intelligence
State pharma manufacturer; AI-discovered compound local scale-up
Open report →
Sits alongside 2 other Atlas profilesThailand Pharmaceutical Manufacturing Market Intelligence
State-owned manufacturer of generics, vaccines, ARV; tier-1 anchor since 1966
Open report →
Sits alongside 4 other Atlas profilesThailand Pharmaceutical Distribution and Wholesale Market Intelligence
State pharma manufacturer, NHSO procurement anchor
Open report →
Sits alongside 2 other Atlas profilesThe Thai Pharma Import Lane: Multinational Brands, Thai-FDA Pathway, and Generic Substitution
Thai state-owned pharmaceutical anchor; structural domestic-generic leader.
Open report →
Sits alongside 5 other Atlas profilesThai Cannabis: From 2022 Decriminalisation to 2025 Recriminalisation and the Industry Whiplash
State-owned pharma; medical-cannabis programme.
Open report →
Sits alongside 5 other Atlas profilesThai Pharmaceutical: GPO State Pharma, Generic Production, and the Patent-Pool ARV Heritage
State-owned pharma; medical-cannabis programme.
Open report →
Sits alongside 5 other Atlas profiles